Search research articles
Contact Us
Filters
Showing results (221-230 of 237) with videos related to
Page
of 24
Sort By:
Clinical Pharmacology and Therapeutics
|
June 3, 2025
CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program
Catherine Chanfreau-Coffinier, Kevin A Friede, Mary E Plomondon, et al.
The Journal of Organic Chemistry
|
November 27, 2018
Highly Diastereoselective Synthesis of a HCV NS5B Nucleoside Polymerase Inhibitor
Yong-Li Zhong, Ed Cleator, Zhijian Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 16, 2025
Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study
A Murray Brunt, Fay H Cafferty, Duncan Wheatley, et al.
Lancet (London, England)
|
June 26, 2020
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
Breast Cancer Research and Treatment
|
September 15, 2021
Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer
Ben P Haynes, Gene Schuster, Richard Buus, et al.
Health Technology Assessment (Winchester, England)
|
November 22, 2023
One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT
Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
Chemotherapy
|
April 28, 2024
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden
James Alexander Korolewicz, Bernhard Scheiner, Claudia A M Fulgenzi, et al.
The Lancet. Oncology
|
May 14, 2026
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
Adrian Murray Brunt, Fay H Cafferty, Anna M Kirby, et al.
The Lancet. Oncology
|
April 10, 2022
Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study
Paul T R Thiruchelvam, Daniel R Leff, Amy R Godden, et al.
Journal of the American College of Cardiology
|
January 17, 2009
Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room
David X Zhao, Marzia Leacche, Jorge M Balaguer, et al.
Page
of 24
Search research articles
Search
Showing results (221-230 of 237) with videos related to
Sort By:
Page
of 24
Clinical Pharmacology and Therapeutics
|
June 3, 2025
CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program
Catherine Chanfreau-Coffinier, Kevin A Friede, Mary E Plomondon, et al.
The Journal of Organic Chemistry
|
November 27, 2018
Highly Diastereoselective Synthesis of a HCV NS5B Nucleoside Polymerase Inhibitor
Yong-Li Zhong, Ed Cleator, Zhijian Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 16, 2025
Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study
A Murray Brunt, Fay H Cafferty, Duncan Wheatley, et al.
Lancet (London, England)
|
June 26, 2020
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
Breast Cancer Research and Treatment
|
September 15, 2021
Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer
Ben P Haynes, Gene Schuster, Richard Buus, et al.
Health Technology Assessment (Winchester, England)
|
November 22, 2023
One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT
Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
Chemotherapy
|
April 28, 2024
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden
James Alexander Korolewicz, Bernhard Scheiner, Claudia A M Fulgenzi, et al.
The Lancet. Oncology
|
May 14, 2026
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
Adrian Murray Brunt, Fay H Cafferty, Anna M Kirby, et al.
The Lancet. Oncology
|
April 10, 2022
Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study
Paul T R Thiruchelvam, Daniel R Leff, Amy R Godden, et al.
Journal of the American College of Cardiology
|
January 17, 2009
Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room
David X Zhao, Marzia Leacche, Jorge M Balaguer, et al.
Page
of 24